New Strategies for Targeting CD38 in Multiple Myeloma Take Root
During the past 5 years, therapies targeting CD38, a protein highly expressed on the surface of plasma cells, have helped fuel the rapidly growing treatment options for patients with multiple myeloma.
COVID-19 Is Expected to Have Long-term Impact on Oncology Practices
The rapidly developing nature of our knowledge about the coronavirus
disease 2019 and the need to respond quickly to the
pandemic are prompting community oncologists to search for ways to maintain
their practices while improving the quality of care for their patients.
Investigators Strive to Refine Paradigm for Penile Cancer Treatment
Investigators are using a novel clinical trial design to test multiple treatment strategies in an effort to define the standard of care in squamous cell carcinoma of the penis.
Subcutaneous Daratumumab Offers Convenience for Patients With Multiple Myeloma
Nearly 5 years after its approval for patients with multiple myeloma, daratumumab is now available in a formulation that can be administered in a fraction of the time required with the original agent.
Oncology Centers Examine the Aftermath of COVID-19 on Clinical Trials
Institutions are slowly but steadily resuming their investigational efforts, examining both the temporary and lasting effects the pandemic has left on their centers.
Niraparib’s Indication Expands in Ovarian Cancer
Bhavana Pothuri, MD, discusses the practice-changing implications of niraparib’s approval in ovarian cancer.
Evaluating the Nonmetastatic CRPC Landscape: What Have We Learned?
A panel of experts provide their insights on how and when they are using novel imaging versus conventional imaging. They also discuss the data regarding the FDA-approved AR-targeted therapies, how they select between them, and their strategies for mitigating any adverse events.
AI Makes Inroads Into Oncology Practice
Oncology practices large and small are starting to tap into the power of data analytics and artificial intelligence to help identify patients at risk of relapse or adverse effects and to assist in making clinical decisions on care.
Profusion of New Drugs Prompts Need for Pragmatic Clinical Trials
The explosion of COVID-19 studies illustrates questions
that have plagued oncology research.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.